September 30, 2021
Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole genome sequencing and machine learning to fight the rise in antibiotic-resistant infections, won the 2021 Disruptive Technology Award from the American Association for Clinical Chemistry (AACC) and People’s Choice Award.
The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. The Disruptive Technology Award recognizes innovative tests and disruptive technology solutions that improve patient care through diagnostic performance or access to high-quality tests. This year’s award focused on artificial intelligence and machine learning technologies that advance medicine and pathology.
Jong Lee, President and CEO, presented the Day Zero technology, along with other finalists Mammoth Biosciences and MeMed, to a panel of expert judges at the AACC 2021 Annual Scientific Meeting held in Atlanta, Georgia. All presented test solutions were judged on feasibility, data support, performance differentiation and disruptive potential. In addition, Day Zero also won the Audience Choice award based on audience votes in the finalists competition.
“We are thrilled to be recognized by AACC as a disruptive technology with the potential to transform patient care,” said Jong Lee, CEO of Day Zero Diagnostics. “The AACC represents the field of clinical laboratory medicine, so it is exceptionally rewarding to be selected by both expert judges and AACC conference attendees as a potentially transformative technology. “
Day Zero is pioneering a new class of culture-free, sequencing-based diagnostics that can modernize the fight against antibiotic-resistant infections. The company is developing a diagnostic system that promises to help patients with serious infections receive the most effective antibiotic treatment on the first day of their hospital admission, day zero, rather than being treated with multiple days of toxic broad-spectrum antibiotics.
About Day Zero Diagnostics
Boston-based Day Zero Diagnostics, Inc., is pioneering a new class of infectious disease diagnostics using whole genome sequencing and machine learning to revolutionize the way the world is combating the growing threat of disease resistance. antibiotics. The company’s mission is to change the way infectious diseases are diagnosed and treated by rapidly identifying both the species and the antibiotic resistance profile of serious infections without the need for a culture. By using sequencing, Day Zero also enables Big Data approaches for the management of outbreaks of nosocomial infections. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital. The company has been recognized as a Leading Innovator by CARB-X, MedTech Innovator, TedMed Hive, Xconomy, HealthTech Arkansas, and MassChallenge HealthTech. For more information visit http://www.dayzerodiagnostics.com or follow us on Twitter at @dayzerodx.
Share the article on social media or by email: